Cargando…

US smokers' reactions to a brief trial of oral nicotine products

BACKGROUND: It has been suggested that cigarette smokers will switch to alternative oral nicotine delivery products to reduce their health risks if informed of the relative risk difference. However, it is important to assess how smokers are likely to use cigarette alternatives before making predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Connor, Richard J, Norton, Kaila J, Bansal-Travers, Maansi, Mahoney, Martin C, Cummings, K Michael, Borland, Ron
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032705/
https://www.ncbi.nlm.nih.gov/pubmed/21219609
http://dx.doi.org/10.1186/1477-7517-8-1
_version_ 1782197487239430144
author O'Connor, Richard J
Norton, Kaila J
Bansal-Travers, Maansi
Mahoney, Martin C
Cummings, K Michael
Borland, Ron
author_facet O'Connor, Richard J
Norton, Kaila J
Bansal-Travers, Maansi
Mahoney, Martin C
Cummings, K Michael
Borland, Ron
author_sort O'Connor, Richard J
collection PubMed
description BACKGROUND: It has been suggested that cigarette smokers will switch to alternative oral nicotine delivery products to reduce their health risks if informed of the relative risk difference. However, it is important to assess how smokers are likely to use cigarette alternatives before making predictions about their potential to promote individual or population harm reduction. OBJECTIVES: This study examines smokers' interest in using a smokeless tobacco or a nicotine replacement product as a substitute for their cigarettes. METHODS: The study included 67 adult cigarette smokers, not currently interested in quitting, who were given an opportunity to sample four alternative oral nicotine products: 1) Camel Snus, 2) Marlboro Snus, 3) Stonewall dissolvable tobacco tablets, and 4) Commit nicotine lozenges. At visit 1, subjects were presented information about the relative benefits/risks of oral nicotine delivery compared to cigarettes. At visit 2, subjects were given a supply of each of the four products to sample at home for a week. At visit 3, subjects received a one-week supply of their preferred product to see if using such products reduced or eliminated cigarette use. RESULTS: After multiple product sampling, participants preferred the Commit lozenges over the three smokeless tobacco products (p = 0.011). Following the one week single-product trial experience, GEE models controlling for gender, age, level of education, baseline cigarettes use, and alternative product chosen, indicated a significant decline in cigarettes smoked per day across one week of single-product sampling (p < 0.01, from 11.8 to 8.7 cigarettes per day), but no change in alternative product use (approximately 4.5 units per day). Biomarkers of exposure showed no change in cotinine, but a 19% reduction in exhaled CO (p < 0.001). CONCLUSIONS: Findings from this study show that smokers, who are currently unwilling to make a quit attempt, may be willing to use alternative products in the short term as a temporary substitute for smoking. However, this use is more likely to be for partial substitution (i.e. they will continue to smoke, albeit at a lower rate) rather than complete substitution. Of the various substitutes offered, smokers were more willing to use a nicotine replacement product over a tobacco-based product.
format Text
id pubmed-3032705
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30327052011-02-03 US smokers' reactions to a brief trial of oral nicotine products O'Connor, Richard J Norton, Kaila J Bansal-Travers, Maansi Mahoney, Martin C Cummings, K Michael Borland, Ron Harm Reduct J Research BACKGROUND: It has been suggested that cigarette smokers will switch to alternative oral nicotine delivery products to reduce their health risks if informed of the relative risk difference. However, it is important to assess how smokers are likely to use cigarette alternatives before making predictions about their potential to promote individual or population harm reduction. OBJECTIVES: This study examines smokers' interest in using a smokeless tobacco or a nicotine replacement product as a substitute for their cigarettes. METHODS: The study included 67 adult cigarette smokers, not currently interested in quitting, who were given an opportunity to sample four alternative oral nicotine products: 1) Camel Snus, 2) Marlboro Snus, 3) Stonewall dissolvable tobacco tablets, and 4) Commit nicotine lozenges. At visit 1, subjects were presented information about the relative benefits/risks of oral nicotine delivery compared to cigarettes. At visit 2, subjects were given a supply of each of the four products to sample at home for a week. At visit 3, subjects received a one-week supply of their preferred product to see if using such products reduced or eliminated cigarette use. RESULTS: After multiple product sampling, participants preferred the Commit lozenges over the three smokeless tobacco products (p = 0.011). Following the one week single-product trial experience, GEE models controlling for gender, age, level of education, baseline cigarettes use, and alternative product chosen, indicated a significant decline in cigarettes smoked per day across one week of single-product sampling (p < 0.01, from 11.8 to 8.7 cigarettes per day), but no change in alternative product use (approximately 4.5 units per day). Biomarkers of exposure showed no change in cotinine, but a 19% reduction in exhaled CO (p < 0.001). CONCLUSIONS: Findings from this study show that smokers, who are currently unwilling to make a quit attempt, may be willing to use alternative products in the short term as a temporary substitute for smoking. However, this use is more likely to be for partial substitution (i.e. they will continue to smoke, albeit at a lower rate) rather than complete substitution. Of the various substitutes offered, smokers were more willing to use a nicotine replacement product over a tobacco-based product. BioMed Central 2011-01-10 /pmc/articles/PMC3032705/ /pubmed/21219609 http://dx.doi.org/10.1186/1477-7517-8-1 Text en Copyright ©2011 O'Connor et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
O'Connor, Richard J
Norton, Kaila J
Bansal-Travers, Maansi
Mahoney, Martin C
Cummings, K Michael
Borland, Ron
US smokers' reactions to a brief trial of oral nicotine products
title US smokers' reactions to a brief trial of oral nicotine products
title_full US smokers' reactions to a brief trial of oral nicotine products
title_fullStr US smokers' reactions to a brief trial of oral nicotine products
title_full_unstemmed US smokers' reactions to a brief trial of oral nicotine products
title_short US smokers' reactions to a brief trial of oral nicotine products
title_sort us smokers' reactions to a brief trial of oral nicotine products
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032705/
https://www.ncbi.nlm.nih.gov/pubmed/21219609
http://dx.doi.org/10.1186/1477-7517-8-1
work_keys_str_mv AT oconnorrichardj ussmokersreactionstoabrieftrialoforalnicotineproducts
AT nortonkailaj ussmokersreactionstoabrieftrialoforalnicotineproducts
AT bansaltraversmaansi ussmokersreactionstoabrieftrialoforalnicotineproducts
AT mahoneymartinc ussmokersreactionstoabrieftrialoforalnicotineproducts
AT cummingskmichael ussmokersreactionstoabrieftrialoforalnicotineproducts
AT borlandron ussmokersreactionstoabrieftrialoforalnicotineproducts